Auteurs
Keywords (en)
Analysis
France
Racine
Analysis
France
Exploration
Accueil
Racine
Racine

Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Pierre Pollak44
Parkinson Disease (drug therapy)89
Pierre Pollak Sauf Parkinson Disease (drug therapy)" 36
Parkinson Disease (drug therapy) Sauf Pierre Pollak" 81
Pierre Pollak Et Parkinson Disease (drug therapy) 8
Pierre Pollak Ou Parkinson Disease (drug therapy) 125
Corpus679
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 8.
Ident.Authors (with country if any)Title
000071 Alexandre Krainik [France] ; Audrey Maillet ; Vanessa Fleury ; Mehmet Sahin ; Irène Troprès ; Laurent Lamalle ; Stephane Thobois ; Valerie Fraix ; Marjorie Villien ; Jan Warnking ; Pierre Pollak ; Serge Pinto ; Paul KrackLevodopa does not change cerebral vasoreactivity in Parkinson's disease.
000460 Aurélie Funkiewiez [France] ; Claire Ardouin [France] ; Paul Krack [France] ; Valérie Fraix [France] ; Nadège Van Blercom [France] ; Jing Xie [France] ; Elena Moro [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France]Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease
000470 Paul Krack [France] ; Valérie Fraix [France] ; Alexandre Mendes [France] ; Alim-Louis Benabid [France] ; Pierre Pollak [France]Postoperative management of subthalamic nucleus stimulation for Parkinson's disease
000536 Christine Dentresangle [France] ; Laurent Veyre [France] ; Didier Le Bars [France] ; Christian Pierre [France] ; Frank Lavenne [France] ; Pierre Pollak [France] ; Jeanine Guerin [France] ; Jean-Claude Froment [France] ; Emmanuel Brousolle [France]Striatal D2 dopamine receptor status in Parkinson's disease: An [18F]dopa and [11C]Raclopride PET study
000545 Yves Agid [France] ; E. Ahlskog [France] ; A. Albanese [France] ; D. Calne [France] ; T. Chase [France] ; J. De Yebenes [France] ; S. Factor [France] ; S. Fahn [France] ; O. Gershanik [France] ; C. Goetz [France] ; W. Koller [France] ; M. Kurth [France] ; A. Lang [France] ; A. Lees [France] ; P. Lewitt [France] ; D. Marsden [France] ; E. Melamed [France] ; P. P. Michel [France] ; Y. Mizuno [France] ; J. Obeso [France] ; W. Oertel [France] ; W. Olanow [France] ; Werner Poewe [France] ; Pierre Pollak [France] ; S. Przedzorski [France] ; N. Quinn [France] ; R. Raisman-Vozari [France] ; A. Rajput [France] ; F. Stocchi [France] ; E. Tolosa [France]Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint
000617 Limousin [France] ; Pierre Pollak [France] ; Abdelhamid Benazzouz [France] ; Dominique Hoffmann [France] ; Emmanuel Broussolle [France] ; Jean Edmond Perret [France] ; Alim-Louis Benabid [France]Bilateral subthalamic nucleus stimulation for severe Parkinson's disease
000638 Broussolle [France] ; L. Cinotti [France] ; Pierre Pollak [France] ; P. Landais [France] ; D. Le Bars [France] ; G. Galy [France] ; F. Lavenne [France] ; Y. Khalfallah [France] ; G. Chazot [France] ; F. Mauguière [France]Relief of akinesia by apomorphine and cerebral metabolic changes in parkinson's disease
000647 H. Allain [France] ; Pierre Pollak [France] ; H. C. Neukirch [France]Symptomatic effect of selegiline in De Novo Parkinsonian patients
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024